Evidence map›Paper›PMID 37034778›Full record

ArticlebioRxiv : the preprint server for biology2023

Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.

Sharon L Freshour, Timothy H-P Chen, Bryan Fisk, Haolin Shen, Matthew Mosior, Zachary L Skidmore, Catrina Fronick, Jennifer K Bolzenius, Obi L Griffith, Vivek K Arora and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sharon L FreshourDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Timothy H-P ChenDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Bryan FiskDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Haolin ShenDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Matthew MosiorDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Zachary L SkidmoreDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Catrina FronickMcDonnell Genome Institute, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Jennifer K BolzeniusDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Obi L GriffithDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Vivek K AroraDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Malachi GriffithDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Washington University in St. Louis · US

Funding

Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision MedicineU24CA237719 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2019 to 2023
$3.8M
Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung CancerU01CA231844 · NCI · WASHINGTON UNIVERSITY · PI GOVINDAN, RAMASWAMY, GRIFFITH, OBI L. · 2018 to 2022
$3.1M
Informatics tools for identification, prioritization and clinical application of neoantigensU01CA248235 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2020 to 2022
$1.3M
DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCERU01CA209936 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2016 to 2018
$1.0M
Integrated Analysis & Interpretation of Whole Genome Exome & Transcriptome SequenR00HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2017 to 2019
$724k
NCI NIH HHS U01 CA209936NCI NIH HHS U01 CA231844NCI NIH HHS U01 CA248235NCI NIH HHS U24 CA237719NHGRI NIH HHS R00 HG007940
6 · The paper itself

Abstract

To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse model of invasive urothelial carcinoma with three conditions: untreated tumor, treated tumor, and tumor treated after CD4+ T cell depletion. After classifying tumor cells based on detection of somatic variants and assigning non-tumor cell types using SingleR, we performed differential expression analysis, overrepresentation analysis, and gene set enrichment analysis (GSEA) within each cell type. GSEA revealed that endothelial cells were enriched for upregulated IFN-g response genes when comparing treated cells to both untreated cells and cells treated after CD4+ T cell depletion. Functional analysis showed that knocking out

Identifiers

PMID37034778
PMCPMC10081275
OpenAlexW4361228324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.